Biosig Technologies Retained Earnings (Accumulated Deficit) 2012-2024 | BSGM
Biosig Technologies retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| Biosig Technologies Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $-255 |
| 2023 | $-245 |
| 2022 | $-216 |
| 2021 | $-189 |
| 2020 | $-157 |
| 2019 | $-105 |
| 2018 | $-71 |
| 2017 | $-57 |
| 2016 | $-44 |
| 2015 | $-32 |
| 2014 | $-23 |
| 2013 | $-14 |
| 2012 | $-4 |
| 2011 | $-1 |
| Biosig Technologies Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-255 |
| 2024-09-30 | $-254 |
| 2024-06-30 | $-252 |
| 2024-03-31 | $-248 |
| 2023-12-31 | $-245 |
| 2023-09-30 | $-239 |
| 2023-06-30 | $-234 |
| 2023-03-31 | $-223 |
| 2022-12-31 | $-216 |
| 2022-09-30 | $-209 |
| 2022-06-30 | $-203 |
| 2022-03-31 | $-197 |
| 2021-12-31 | $-189 |
| 2021-09-30 | $-180 |
| 2021-06-30 | $-173 |
| 2021-03-31 | $-165 |
| 2020-12-31 | $-157 |
| 2020-09-30 | $-147 |
| 2020-06-30 | $-135 |
| 2020-03-31 | $-116 |
| 2019-12-31 | $-105 |
| 2019-09-30 | $-90 |
| 2019-06-30 | $-85 |
| 2019-03-31 | $-77 |
| 2018-12-31 | $-71 |
| 2018-09-30 | $-65 |
| 2018-06-30 | $-62 |
| 2018-03-31 | $-56 |
| 2017-12-31 | $-57 |
| 2017-09-30 | $-52 |
| 2017-06-30 | $-50 |
| 2017-03-31 | $-47 |
| 2016-12-31 | $-44 |
| 2016-09-30 | $-42 |
| 2016-06-30 | $-41 |
| 2016-03-31 | $-35 |
| 2015-12-31 | $-32 |
| 2015-09-30 | $-30 |
| 2015-06-30 | $-31 |
| 2015-03-31 | $-26 |
| 2014-12-31 | $-23 |
| 2014-09-30 | $-20 |
| 2014-06-30 | $-16 |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2012-12-31 | $-4 |
| 2011-12-31 | $-1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.033B | $0.000B |
| BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company's first product, PURE EP (tm) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. | |||